Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

Biotechnology

Healthcare
$7.06 -2.70%

-$0.26 today

Market cap
$618.50M
Beta
2.00
P/E (TTM)
-5.1
EPS (TTM)
-$1.80
52W Low $4.02High $36.26

Volume 1.18M

Average 1.27M

OLMA Net Income

Bottom-line profit after all expenses, interest, and taxes.

Olema Pharmaceuticals, Inc.NASDAQ: OLMA

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$53.09M, compared with -$30.39M a year earlier. Trailing-twelve-month net income was -$185.15M.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 6 analysts of -$194.5M (-19.7%) for the fiscal year ending Dec 2026, a step up from the -25.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$53.09M-15.3% QoQ
Last fiscal yearDec 2025
-$162.45M-25.5% YoY
LTMMar 2026
-$185.15M-43.6% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-74.7%-29.7%+45.0 pp
1 year-25.5%-19.7%+5.7 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(162.45M) USD
Year-over-year change
-25.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How OLMA compares with its peers on the latest reported figures

  • OLMA's LTM Mar 2026 net income of -$185.15M is the lowest of the 2 companies compared; the peer median is $24.38M.
  • Its year-over-year change of -43.6% is the lowest of 2, against a peer median of -35.9%.
OLMA Competitors Peer median
Net Income for OLMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$24.38M -35.9%+2396.3%10.7%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$185.15M -43.6%——
Peer median (excluding OLMA) $24.38M-35.9%+2396.3%10.7%

Competitors are the stored peer set for OLMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development51.1M82.27M86.14M124.52M157.7M
Selling, General & Admin20.39M24.71M18.82M17.74M21M
Operating Expenses71.49M106.99M104.96M142.26M178.7M
Depreciation & Amortization163K357K377K393K490K
EBITDA(70.93M)(104.43M)(96.28M)(129.08M)(161.96M)
EBITDA Margin—————
Operating Income(71.49M)(106.99M)(104.96M)(142.26M)(178.7M)
Operating Margin—————
Interest Income442K2.23M8.32M12.68M16.22M
Interest Expense—0—00
Other Income / Expenses395K2.2M8.31M12.78M16.25M
Income Before Tax(71.1M)(104.79M)(96.66M)(129.47M)(162.45M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(71.1M)(104.79M)(96.66M)(129.47M)(162.45M)
Net Margin—————
EPS (Basic)(1.79)(2.62)(2.14)(2.20)(1.87)
EPS (Diluted)(1.79)(2.62)(2.14)(2.20)(1.87)
Weighted Avg Shares39.52M40M45.25M58.74M87.01M
Weighted Avg Shares (Diluted)39.52M40M45.25M58.74M87.01M

Olema Pharmaceuticals, Inc.

NASDAQ:OLMA

Intrinsic Alpha fair value

Locked

Current Price

$7.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.